198 related articles for article (PubMed ID: 18559494)
21. Critical role for c-FLIP(L) on Fas resistance in colon carcinoma cell line HT-29.
Zang F; Sun B; Zhao X; Niu R; Zhang S; Yu M; Wei X; Zhang L
Cell Biol Int; 2008 Mar; 32(3):329-36. PubMed ID: 18243739
[TBL] [Abstract][Full Text] [Related]
22. [Relationship between the Akt-regulated direct p53 mitochondrial translocation and the resistance to cisplatin of ovarian cancer cells].
Zhou Y; Wang SY; Yang XK; Wang HM
Zhonghua Zhong Liu Za Zhi; 2011 Feb; 33(2):97-100. PubMed ID: 21575475
[TBL] [Abstract][Full Text] [Related]
23. Calpain-mediated processing of p53-associated parkin-like cytoplasmic protein (PARC) affects chemosensitivity of human ovarian cancer cells by promoting p53 subcellular trafficking.
Woo MG; Xue K; Liu J; McBride H; Tsang BK
J Biol Chem; 2012 Feb; 287(6):3963-75. PubMed ID: 22117079
[TBL] [Abstract][Full Text] [Related]
24. Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment.
Bagnoli M; Balladore E; Luison E; Alberti P; Raspagliesi F; Marcomini B; Canevari S; Mezzanzanica D
Mol Cancer Ther; 2007 Feb; 6(2):762-72. PubMed ID: 17308072
[TBL] [Abstract][Full Text] [Related]
25. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
Biochem Pharmacol; 2009 Apr; 77(8):1328-36. PubMed ID: 19426671
[TBL] [Abstract][Full Text] [Related]
26. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
Ali AY; Abedini MR; Tsang BK
Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
[TBL] [Abstract][Full Text] [Related]
27. Sensitizing glioma cells to cisplatin by abrogating the p53 response with antisense oligonucleotides.
Datta K; Shah P; Srivastava T; Mathur SG; Chattopadhyay P; Sinha S
Cancer Gene Ther; 2004 Aug; 11(8):525-31. PubMed ID: 15167899
[TBL] [Abstract][Full Text] [Related]
28. Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations.
Yan XD; Li M; Yuan Y; Mao N; Pan LY
Oncol Rep; 2007 May; 17(5):1163-9. PubMed ID: 17390060
[TBL] [Abstract][Full Text] [Related]
29. GADD45A is a mediator of CD437 induced apoptosis in ovarian carcinoma cells.
Jiang T; Soprano DR; Soprano KJ
J Cell Physiol; 2007 Sep; 212(3):771-9. PubMed ID: 17474084
[TBL] [Abstract][Full Text] [Related]
30. The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin.
Hrstka R; Powell DJ; Kvardova V; Roubalova E; Bourougaa K; Candeias MM; Sova P; Zak F; Fåhraeus R; Vojtĕsek B
Anticancer Drugs; 2008 Apr; 19(4):369-79. PubMed ID: 18454047
[TBL] [Abstract][Full Text] [Related]
31. Lisofylline sensitizes p53 mutant human ovarian carcinoma cells to the cytotoxic effects of cis-diamminedichloroplatinum (II).
Husain A; Rosales N; Schwartz GK; Spriggs DR
Gynecol Oncol; 1998 Jul; 70(1):17-22. PubMed ID: 9698467
[TBL] [Abstract][Full Text] [Related]
32. c-FLIP gene silencing eliminates tumor cells in breast cancer xenografts without affecting stromal cells.
Day TW; Sinn AL; Huang S; Pollok KE; Sandusky GE; Safa AR
Anticancer Res; 2009 Oct; 29(10):3883-6. PubMed ID: 19846923
[TBL] [Abstract][Full Text] [Related]
33. Establishment of cisplatin-resistant ovarian yolk sac tumor cells and investigation of the mechanism of cisplatin resistance using this cell line.
Shibata K; Umezu T; Sakurai M; Kajiyama H; Yamamoto E; Ino K; Nawa A; Kikkawa F
Gynecol Obstet Invest; 2011; 71(2):104-11. PubMed ID: 21150160
[TBL] [Abstract][Full Text] [Related]
34. The role of c-FLIP in cisplatin resistance of human bladder cancer cells.
Lee S; Yoon CY; Byun SS; Lee E; Lee SE
J Urol; 2013 Jun; 189(6):2327-34. PubMed ID: 23313194
[TBL] [Abstract][Full Text] [Related]
35. Flow cytometric measurement of cellular FLICE-inhibitory protein (c-FLIP) in ovarian carcinoma effusions.
Dong HP; Ree Rosnes AK; Bock AJ; Holth A; Flørenes VA; Trope' CG; Risberg B; Davidson B
Cytopathology; 2011 Dec; 22(6):373-82. PubMed ID: 22032542
[TBL] [Abstract][Full Text] [Related]
36. p53 is required for cisplatin-induced processing of the mitochondrial fusion protein L-Opa1 that is mediated by the mitochondrial metallopeptidase Oma1 in gynecologic cancers.
Kong B; Wang Q; Fung E; Xue K; Tsang BK
J Biol Chem; 2014 Sep; 289(39):27134-27145. PubMed ID: 25112877
[TBL] [Abstract][Full Text] [Related]
37. Myricetin sensitizes malignant glioma cells to TRAIL-mediated apoptosis by down-regulation of the short isoform of FLIP and bcl-2.
Siegelin MD; Gaiser T; Habel A; Siegelin Y
Cancer Lett; 2009 Oct; 283(2):230-8. PubMed ID: 19398149
[TBL] [Abstract][Full Text] [Related]
38. The XIAP inhibitor Embelin enhances TRAIL-mediated apoptosis in malignant glioma cells by down-regulation of the short isoform of FLIP.
Siegelin MD; Gaiser T; Siegelin Y
Neurochem Int; 2009 Nov; 55(6):423-30. PubMed ID: 19409438
[TBL] [Abstract][Full Text] [Related]
39. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
[TBL] [Abstract][Full Text] [Related]
40. Clock gene mouse period2 overexpression inhibits growth of human pancreatic cancer cells and has synergistic effect with cisplatin.
Oda A; Katayose Y; Yabuuchi S; Yamamoto K; Mizuma M; Shirasou S; Onogawa T; Ohtsuka H; Yoshida H; Hayashi H; Rikiyama T; Kim H; Choe Y; Kim K; Son H; Motoi F; Egawa S; Unno M
Anticancer Res; 2009 Apr; 29(4):1201-9. PubMed ID: 19414365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
